Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
First Claim
Patent Images
1. A purified cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein:
- n is 4, 5 or 6;
R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and
S1, S2, S3, S4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition shows an absence of underivatized cyclodextrin as measured by thin-layer chromatography.
2 Assignments
0 Petitions
Accused Products
Abstract
Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
612 Citations
45 Claims
-
1. A purified cyclodextrin derivative composition which comprises a cyclodextrin derivative of formula ##STR3## wherein:
- n is 4, 5 or 6;
R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each, independently, O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and S1, S2, S3, S4, S5, S6, S7, S8 and S9 are each, independently, a pharmaceutically acceptable cation, and wherein said composition shows an absence of underivatized cyclodextrin as measured by thin-layer chromatography. - View Dependent Claims (2, 3, 4, 5, 6, 7, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 43, 45)
- n is 4, 5 or 6;
-
8. A composition comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR4## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each at least one of R1 and R2 is, independently, said O--(C 2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin. - View Dependent Claims (9, 10, 11, 12, 13, 36, 37, 38, 39, 40)
- ##STR4## wherein;
-
14. A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a clathrate complex comprising a drug complexed to a cyclodextrin derivative of formula (2):
- ##STR5## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O--(C2-6 alkylene)--SO3- group, and at least one of R1 and R2 is, independently, said O--(C2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation; wherein said composition contains not more than 5 wt. % of underivatized cyclodextrin. - View Dependent Claims (15, 41, 42, 44)
- ##STR5## wherein;
-
16. A delayed release pharmaceutical composition, comprising a drug complexed to a purified cyclodextrin derivative of formula (2):
- ##STR6## wherein;
n=4, 5 or 6;R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently O- or a O--(C2-6 alkylene)SO3- group, and at least one of R1 and R2 is, independently said O--(C2-6 alkylene)--SO3- group; and S1 to S9 are each, independently, a pharmaceutically acceptable cation.
- ##STR6## wherein;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUniversity of Kansas
-
Original AssigneeUniversity of Kansas
-
InventorsStella, Valentino, Rajewski, Roger
-
Primary Examiner(s)Griffin, Ronald W.
-
Application NumberUS07/469,087Time in Patent Office917 DaysField of Search536/103, 514/58, 514/778, 514/964, 514/965US Class Current514/58CPC Class CodesA61K 47/6951 using cyclodextrin cyclodex...B82Y 5/00 Nanobiotechnology or nanome...C08B 37/0012 Cyclodextrin [CD], e.g. cyc...C08L 5/16 Cyclodextrin; Derivatives t...
